Overview

Avalglucosidase Alfa Extension Study

Status:
Active, not recruiting

Trial end date:
2022-03-18

Target enrollment:

Participant gender:

Summary

Primary Objective: Long-term safety and pharmacokinetics (PK) of avalglucosidase alfa Secondary Objective: Long-term effect of avalglucosidase alfa on pharmacodynamic and exploratory efficacy variables

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Genzyme, a Sanofi Company